Alzheimer’s disease biomarkers in cognitively normal adults

Takeaway

  • Early changes in cerebrospinal fluid (CSF) amyloid-β (Aβ) occur in preclinical Alzheimer’s disease (AD), with changes in neuronal injury and neurodegeneration markers possibly occurring closer in time to cognitive decline.

Why this matters

  • Multiple studies show evidence that the neuropathological course of AD is long and dynamic, with some changes occurring prior to clinical or cognitive symptom onset and some after; however, the sequence of these changes has not been explored in detail.

  • The incidence of AD is growing at a much faster rate versus available reliable treatments; therefore, a better understanding of the order of changes in AD may contribute to the development of specific therapeutic agents targeting different stages of the disease.